OOIR: Observatory of International Research

Papers

(The H4-Index of Critical Reviews in Oncology Hematology is 40. The table below lists those papers that are above that threshold based on CrossRef citation counts [max. 250 papers]. The publications cover those that have been published in the past four years, i.e., from 2020-11-01 to 2024-11-01.)

Article	Citations
Molecular testing and targeted therapy for non-small cell lung cancer: Current status and perspectives	285
ctDNA as a cancer biomarker: A broad overview	155
TMB or not TMB as a biomarker: That is the question	139
The impact of gender on The efficacy of immune checkpoint inhibitors in cancer patients: The MOUSEION-01 study	111
Beyond EGFR, ALK and ROS1: Current evidence and future perspectives on newly targetable oncogenic drivers in lung adenocarcinoma	97
Unmet supportive care needs of people with advanced cancer and their caregivers: A systematic scoping review	88
Gynecologic cancers and non-coding RNAs: Epigenetic regulators with emerging roles	86
Ferroptosis: An emerging approach for targeting cancer stem cells and drug resistance	81
Immune system in cancer radiotherapy: Resistance mechanisms and therapy perspectives	81
Characteristics of gastric cancer around the world	76
International liquid biopsy standardization alliance white paper	72
Chronic inflammation towards cancer incidence: A systematic review and meta-analysis of epidemiological studies	68
Mechanistic role of HPV-associated early proteins in cervical cancer: Molecular pathways and targeted therapeutic strategies	67
Breast cancer, screening and diagnostic tools: All you need to know	67
Can mHealth interventions improve quality of life of cancer patients? A systematic review and meta-analysis	67
New advances in exosome-based targeted drug delivery systems	62
Emerging role of exosomes as biomarkers in cancer treatment and diagnosis	62
Liquid biopsy in bladder cancer: State of the art and future perspectives	59
Immunotherapy addition to neoadjuvant chemotherapy for early triple negative breast cancer: A systematic review and meta-analysis of randomized clinical trials	59
Prospects of targeting PI3K/AKT/mTOR pathway in pancreatic cancer	58
The main sources of circulating cell-free DNA: Apoptosis, necrosis and active secretion	58
Immunotherapy for head and neck cancer: Present and future	56
Comprehensive review of chromophobe renal cell carcinoma	55
Mortality in adult patients with solid or hematological malignancies and SARS-CoV-2 infection with a specific focus on lung and breast cancers: A systematic review and meta-analysis	50
Reactive oxygen species (ROS): Critical roles in breast tumor microenvironment	50

Immune evasion mechanisms in acute myeloid leukemia: A focus on immune checkpoint pathways	49
Platelet-mediated tumor metastasis mechanism and the role of cell adhesion molecules	47
PD-L1 expression and Tumor mutation burden as Pathological response biomarkers of Neoadjuvant immunotherapy for Early-stage Non-small cell lung cancer: A systematic review and meta-analysis	46
Extranodal NK/T cell lymphoma, nasal type: An updated overview	46
Melanoma of unknown primary: New perspectives for an old story	45
Exercise for individuals with bone metastases: A systematic review	45
Obesity and prostate cancer: A narrative review	43
The tumor-agnostic treatment for patients with solid tumors: a position paper on behalf of the AIOM- SIAPEC/IAP-SIBioC-SIF Italian Scientific Societies	43
Molecular landscape of recurrent cervical cancer	42
Latest evidence on immune checkpoint inhibitors in metastatic colorectal cancer: A 2022 update	42
Apigenin in cancer prevention and therapy: A systematic review and meta-analysis of animal models	42
miR-26 family and its target genes in tumorigenesis and development	42
Next generation diagnostic algorithm in non-small cell lung cancer predictive molecular pathology: The KWAY Italian multicenter cost evaluation study	41
Interactions between androgen receptor signaling and other molecular pathways in prostate cancer progression: Current and future clinical implications	41
Triple negative breast cancer in the era of miRNA	41
The clinical utility of microsatellite instability in colorectal cancer	40
Prevention and treatment of FGFR inhibitor-associated toxicities	40